Equities

Delta-Fly Pharma Inc

4598:TYO

Delta-Fly Pharma Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)656.00
  • Today's Change-22.00 / -3.24%
  • Shares traded446.70k
  • 1 Year change-46.14%
  • Beta0.2671
Data delayed at least 20 minutes, as of Nov 13 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,4178441,268
Total Receivables, Net------
Total Inventory------
Prepaid expenses2.613.235.51
Other current assets, total13196.80
Total current assets1,4338661,281
Property, plant & equipment, net383940
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets1.981.983.02
Total assets1,4749071,324
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total24111691
Total current liabilities24111691
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total0.00--0.00
Total liabilities24111691
SHAREHOLDERS EQUITY
Common stock4,7313,7953,352
Additional paid-in capital4,7113,7753,332
Retained earnings (accumulated deficit)(8209)(6779)(5451)
Treasury stock - common(0.34)(0.34)(0.3)
Unrealized gain (loss)------
Other equity, total0.00----
Total equity1,2337911,233
Total liabilities & shareholders' equity1,4749071,324
Total common shares outstanding8.236.375.42
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.